Related Experiment Video
Updated: Jun 9, 2025
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Clinical approach for pulmonary alveolar proteinosis in children
Anuvat Klubdaeng1, Prakarn Tovichien2
1Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Insights
Pulmonary alveolar proteinosis (PAP) is a rare lung disease caused by surfactant buildup. Understanding its diverse causes, from genetic mutations to environmental factors, is crucial for effective diagnosis and treatment.
Area of Science:
- Pulmonology
- Rare Diseases
- Genetics
Background:
- Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by excessive surfactant accumulation in alveoli.
- PAP is classified into primary, secondary, congenital, and unclassified forms, with distinct underlying mechanisms.
- Primary PAP involves disrupted granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling, leading to impaired surfactant clearance by alveolar macrophages.
Discussion:
- Autoimmune PAP results from anti-GM-CSF antibodies, while hereditary PAP stems from GM-CSF receptor gene mutations.
- Secondary PAP arises from conditions affecting alveolar macrophage function or number, including infections and toxin exposure.
- Congenital PAP is associated with mutations in genes responsible for surfactant protein production.
Key Insights:
- Diagnostic hallmarks include a 'crazy-paving' pattern on CT scans, diffuse ground-glass opacities, and septal thickening.
- Bronchoalveolar lavage fluid and histology confirm PAP but not its specific etiology.
- Treatment often involves whole lung lavage, supplemented by cause-specific therapies.
Outlook:
- Further research into the specific genetic and immunological pathways of PAP subtypes is warranted.
- Developing targeted therapies based on the precise cause of PAP could improve patient outcomes.
- Early and accurate diagnosis, considering age-specific etiologies, is essential for managing this rare lung condition.
Abstract:
In this editorial, we discuss the clinical implications of the article by Zhang et al. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by excessive surfactant accumulation in the alveoli. It is classified into four categories: Primary, secondary, congenital, and unclassified forms. Primary PAP is caused by the disruption of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor signaling, which is necessary for the clearance of surfactant by alveolar macrophages. It is further divided into autoimmune PAP, caused by anti-GM-CSF antibodies blocking alveolar macrophage activation, and hereditary PAP, resulting from mutations in genes encoding GM-CSF receptors. Secondary PAP develops due to conditions affecting the number or function of alveolar macrophages, such as infections, immunodeficiency, hematological disorders, or exposure to inhaled toxins. Congenital PAP is linked to mutations in genes involved in surfactant protein production. Notably, the causes of PAP differ between children and adults. Diagnostic features include a characteristic "crazy-paving" pattern on high-resolution computed tomography, accompanied by diffuse ground-glass opacities and interlobular septal thickening. The presence of PAP can be identified by the milky appearance of bronchoalveolar lavage fluid and histological evaluation. However, these methods cannot definitively determine the cause of PAP. Whole lung lavage remains the standard treatment, often combined with specific therapies based on the underlying cause.
